Follow us on:

Cambridge Cognition CEO Dr Matthew Stork ‘Strategy paying off’ with significant new contract win (Interview)

Cambridge Cognition plc (LON:COG) CEO Dr Matthew Stork joins DirectorsTalk to discuss a contract win for three phase II studies with a new pharmaceutical client. Matthew provides us with some background on the company and its business model, provides more details around the win and what it means strategically and the effects the company is seeing with regards to Covid-19.

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

Find more news, interviews, share price & company profile here for:Cambridge Cognition Holdings plc

Share this interview

Other Interviews

More News

Cambridge Cognition Renewed promise for early Alzheimer’s drug signals potential for COG October 25, 2019
Cambridge Cognition Holdings plc first half successes across a number of areas September 19, 2019
Cambridge Cognition Holdings Plc Excellent product prospects August 27, 2019
Cambridge Cognition expands further into Chinese market August 12, 2019
Cambridge Cognition Holdings Plc New Commercial Partnership and Further Scientific Validation for NeuroVocalix July 19, 2019
Cambridge Cognition Holdings Plc Appoints Debra Leeves as a Non-Executive Director July 1, 2019
Cambridge Cognition Holdings Plc Annual Report & Notice of AGM May 1, 2019
Cambridge Cognition Holdings Plc Changes to the board April 25, 2019
Cambridge Cognition Holdings Plc Grant of Options April 17, 2019
Cambridge Cognition Holdings Plc Wins £1.3m digital health contract March 19, 2019

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.